All Programs

Use the tool below to view all available Global Oncology Academy Series

Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
Global Oncology Academy
Navigating Metastatic Breast Cancer Care: Key Factors in Decision-Making
- Paolo Tarantino, MD
First-line Chemotherapy Options in Metastatic PDAC
First-line Chemotherapy Options in Metastatic PDAC
MinuteCE®
First-line Chemotherapy Options in Metastatic PDAC
0.25 program credits
- Eileen O’Reilly, MD
0.25 program credits
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Project Oncology®
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
- Fernando López-Ríos, MD, PhD
- Christian Rolfo, MD, PhD
- Charlie Gourley, MD, PhD
Targeting CD123 in AML: The Latest Therapeutic Advancements
Targeting CD123 in AML: The Latest Therapeutic Advancements
Project Oncology®
Targeting CD123 in AML: The Latest Therapeutic Advancements
- Jennifer Caudle, DO
- Naval Daver, MD
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
Global Oncology Academy
Prostate Cancer Care: Testosterone Therapy’s Impact on Biochemical Recurrence
- Mohit Khera, M.D., M.B.A., M.P.H.
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Clinician's Roundtable
Examining the Role of Bacterial Biofilms in Colorectal Cancer Screening
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
Global Oncology Academy
Slowing Prostate Cancer Progression: The Role of Dietary Fat Modifications
- William Aronson, MD
From Diagnosis to Treatment: Challenges in Glioblastoma Care
From Diagnosis to Treatment: Challenges in Glioblastoma Care
NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care
- Lauren Schaff, MD
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Project Oncology®
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Project Oncology®
Unresectable Hepatocellular Carcinoma Care: Investigating a Combination Therapy
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credit
- Daniel P. Petrylak, MD
- Elizabeth R. Plimack, MD, MS, FASCO
- Evan Y. Yu, MD
1.00 credit
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
Project Oncology®
Nanrilkefusp Alfa: A Promising Subcutaneous IL-15Rβγ Superagonist
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
Project Oncology®
AML Care: Examining the Efficacy and Safety of a Triplet Combination Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Anthony Stein, MD

All Programs

Popular

NEED HELP?

Contact us

NEED HELP?

Contact us

All Programs

Popular

Title

Share on ReachMD

Welcome to the newGlobal Oncology Academy website.

Welcome to the new
Global Oncology Academy website.